Alison Mcvie-Wylie, PhD

Title: Vice President, Disease Area Executive, DMD

Organization: Vertex Pharmaceutical

Bio: Alison McVie-Wylie is the Vice President, Disease Area Executive, Duchenne Muscular Dystrophy at Vertex. Prior to Vertex, Alison led Preclinical Development at Exonics Therapeutics and served as the Head of Rare Disease Gene Therapy and Biologics Pharmacology at Sanofi-Genzyme. Alison was the lead Scientist responsible for the nonclinical development of Myozyme from early concept to marketing approval. Alison obtained her Ph.D. in Molecular Genetics from the University of Glasgow, Scotland.

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

See more from same speaker

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

See more from same speaker

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

See more from same speaker

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

See more from same speaker

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

See more from same speaker

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Genine Winslow, MSc

CEO & President

Chameleon Biosciences

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

Gene Therapy and Gene Editing Symposium

A brief overview of the strategy guiding efforts in gene therapy and gene editing, as well as critical updates from the companies in this space. Moderated discussion included.

Jeffrey Chamberlain, PhD

Moderators

See more from same speaker

Reed Clark, PhD

Chief Science Officer, Ultragenyx Gene Therapy

Ultragenyx

See more from same speaker

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

See more from same speaker

Jennifer Hodge, PhD

Team Lead, Rare Neurology USMA

Pfizer

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years